Relay Therapeutics Inc
NASDAQ:RLAY
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
4.16
12.07
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Relay Therapeutics Inc
Relay Therapeutics Inc
Capital Expenditures
Relay Therapeutics Inc
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Relay Therapeutics Inc
NASDAQ:RLAY
|
Capital Expenditures
-$4.1m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Capital Expenditures
-$888m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-4%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Capital Expenditures
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Capital Expenditures
-$974m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-1%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Capital Expenditures
-$508.9m
|
CAGR 3-Years
-32%
|
CAGR 5-Years
-47%
|
CAGR 10-Years
-26%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Capital Expenditures
-$928.1m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-13%
|
|
Relay Therapeutics Inc
Glance View
Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The company is headquartered in Cambridge, Massachusetts and currently employs 245 full-time employees. The company went IPO on 2020-07-16. The firm is focused on transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The firm is advancing a pipeline of medicines to address targets in precision oncology, including its lead product candidates, RLY-4008, RLY-2608 and RLY-1971. Its RLY-1971 binds and stabilizes Src homology region two (SH2)-containing protein tyrosine phosphatase two (SHP2) in its inactive conformation. Its RLY-4008, is it inhibitor of fibroblast growth factor receptor 2 (FGFR2), enriched for patients with advanced solid tumors having oncogenic FGFR2. The firm uses its Dynamo platform to focus on precision oncology. The company is also advancing several early programs focused on other precision oncology and genetic disease targets.
See Also
What is Relay Therapeutics Inc's Capital Expenditures?
Capital Expenditures
-4.1m
USD
Based on the financial report for Dec 31, 2023, Relay Therapeutics Inc's Capital Expenditures amounts to -4.1m USD.
What is Relay Therapeutics Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
-20%
Over the last year, the Capital Expenditures growth was 54%. The average annual Capital Expenditures growth rates for Relay Therapeutics Inc have been -29% over the past three years , -20% over the past five years .
You don't have any saved screeners yet
